Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism.

doi:10.1016/j.phrs.2021.105767

Paper

Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism.

Published Jul 14, 2021 · Sijing Dong, Min Zhu, Ke Wang

Pharmacological research

Q1 SJR score

107

Citations

2

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Rigorous Journal

Highly Cited

Study Snapshot

Dihydromyricetin improves colitis symptoms in mice by restoring gut microbiota and microbial bile acid metabolism, potentially targeting inflammation and improving intestinal barrier function.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Dihydromyricetin improves DSS-induced colitis in mice via modulation of fecal-bacteria-related bile acid metabolism.

Sign up to use Study Snapshot

References

Citations

Dihydromyricetin: an emerging compound with comprehensive effects on multiple systems

Dihydromyricetin (DHM) exhibits anti-inflammatory, antioxidant, anti-tumor, and anti-viral activities, offering potential clinical applications in various systems.

Promotion of healthy aging through the nexus of gut microbiota and dietary phytochemicals.

Dietary phytochemicals and gut microbiota work together to promote healthy aging by influencing gut barrier integrity, immune function, mitochondria function, and oxidative stress.

Atractylodes macrocephala Koidz polysaccharide ameliorates DSS-induced colitis in mice by regulating the gut microbiota and tryptophan metabolism.

PAMK alleviates DSS-induced colitis in mice by regulating gut microbiota and tryptophan metabolism, supporting its potential development as a new clinical drug against UC.

Type 5 Resistant Starch Can Effectively Alleviate Experimentally Induced Colitis in Mice by Modulating Gut Microbiota.

Type 5 resistant starch effectively alleviates colitis symptoms in mice by improving gut microflora dysbiosis and stimulating the generation of short-chain fatty acids.

Long-term effects of Nε-carboxymethyllysine intake on intestinal barrier permeability: Associations with gut microbiota and bile acids.

Long-term N-carboxymethyllysine intake increases intestinal permeability and alters gut microbiota composition, highlighting the chronic health risks of processed foods.

Smoking, coffee intake, and Parkinson's disease: potential protective mechanisms and components.

Smoking and coffee drinking may reduce the risk of Parkinson's disease due to phenolic compounds in tobacco and coffee, which inhibit neuroinflammation, activate the Nrf2 pathway, and alter the gut microbiome.

Bile Acids in Inflammatory Bowel Disease: From Pathophysiology to Treatment

Bile acids play a complex role in inflammatory bowel disease, offering promising new therapeutic targets for treating the condition and improving patient outcomes.

Dihydromyricetin/montmorillonite intercalation compounds ameliorates DSS-induced colitis: Role of intestinal epithelial barrier, NLRP3 inflammasome pathway and gut microbiota.

DHM/MMT intercalation compounds show promising potential for treating ulcerative colitis by restoring intestinal mucosa and modulating gut microbiota, primarily through inhibition of the NLRP3 signaling pathway.